Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib versus hydroxycarbamide or interferon as first-line therapy in high-risk polycythaemia vera
ISRCTN12885480Phase 3Recruiting
- Sponsor
- University of Birmingham
- Start
- Sep 2019
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of ruxolitinib, hydroxyurea and interferon alfa in polycythemia vera (PV) (2 arms), sponsored by University of Birmingham. Primary endpoint: Event-free survival. Started Sep 2019; status: recruiting.
02
Drugs
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on ISRCTN12885480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12885480.